Clinical Genomics names Mark Boyle president of in vitro diagnostics: 3 things to know

Bridgewater, N.J.-based Clinical Genomics, a biotechnology company focused on colorectal cancer diagnosis, has appointed Mark Boyle to president of in vitro diagnostics.

Advertisement

Here’s what you need to know about Mr. Boyle:

1. He has 26 years of commercial experience in the in vitro diagnostics and life sciences industry.

2. Prior to joining Clinical Genomics, he served as vice president of Qiagen. In this role, he led the company’s business portfolio in tuberculosis management.

3. His other positions include president of Cellestis and general manager of the United Kingdom subsidiary of Diagnostic Systems Laboratories.

More articles on gastroenterology and endoscopy:

Which lifestyle factors are associated with serrated colorectal polyps? 5 study insights
AGA critiques ABIM maintenance of certification announcement: 3 takeaways
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.